Business

MediPharm Labs Completes Export of Medical Cannabis to Barbados, Canadian Business Journal

  • Patient-based delivery of medical cannabis with the approval of both Barbados and Canadian health authorities.
  • This is the fourth new country that MediPharm Labs entered in 2021, following the first shipments to Germany, Brazil and Peru.

Barrie, Ontario, November 26, 2021 (GLOBE NEWSWIRE) — MediPharm Labs Corp.. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or “Company”) A pharmaceutical company specializing in precision-based cannabinoids has announced that it has completed the export of medical cannabis to Barbados. bottom. Partnership with strategic partner Avicanna (TSX: AVCN).

“Our GMP platform is a reliable partner for companies looking to access global medical cannabis programs,” said Bryan Howcroft, CEO of MediPharm Labs. “As countries around the world continue to adopt medical cannabis programs, MediPharm Labs will serve these markets as the only North American producer with a Good Manufacturing Practice (GMP) for the extraction of natural cannabinoids. It’s in the best position to do. “

The company has manufactured and delivered Avicanna RHO Phyto products to the Caribbean healthcare community and patients through Bridenstokes, a well-established health drug distributor in the Caribbean. These advanced cannabis products are evidence-based and are sold through the Avicanna Education Platform for patient support, marketing, training and more.

MediPharm Labs will implement a medical cannabis program and continue to provide it to international jurisdictions. This practice is a proof-of-concept for future drug customers who choose MediPharm Labs to manufacture new and generic drugs with the marketing approval of physician prescriptions in regions such as the United States and the European Union.

About MediPharm Labs

Founded in 2015, MediPharm Labs utilizes a Good Manufacturing Practices accredited facility with ISO-compliant clean rooms to purify pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (APIs), and advanced derivatives. Specializes in the development and manufacturing of. MediPharm Labs has five key extraction lines to provide customers with pure, reliable and precisely administered cannabis products, with experts, research-led teams, state-of-the-art technology, downstream purification methodologies. Invested in a dedicated facility. MediPharm Labs formulates, develops (including sensory testing), processes, packages, and distributes cannabis extracts and advanced cannabinoid-based products to the domestic and international markets through wholesale and white-label platforms.

In 2021, MediPharm Labs obtained a drug establishment license from Health Canada and became the only North American good manufacturing license for the extraction of natural cannabinoids. We operate in compliance with all applicable laws in the countries in which we operate.

Future outlook notes:

This news release contains “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”) within the meaning of applicable Canadian securities law. increase. All statements, except historical facts, are forward-looking statements and are based on expectations, estimates, and forecasts as of the date of this news release. All statements containing discussions about predictions, expectations, beliefs, plans, predictions, objectives, assumptions, future events or performance (often with phrases such as “expect”, “not expect”, “expected” Use, but not always), “anticipate” or “not anticipate”, “plan”, “budget”, “plan”, “forecast”, “estimate”, “believe” or “intention” “To” or a variation of such a word or phrase, or to state a particular action, an event or result “possible” or “possible”, “possible”, “possible” or “Possible” or “achieved”) may be a statement of future prospects rather than a statement of historical facts. In this news release, forward-looking statements are specifically related to the following: Be a reliable partner for companies looking to access global medical cannabis programs. Be in the best position to serve countries around the world that have adopted a medical cannabis program. Continue delivery to international jurisdictions. Future pharmaceutical customers; We manufacture new and generic drugs with marketing approval for physician prescriptions in regions such as the United States and the European Union. Forward-looking statements are considered reasonable, but may differ materially from known and unknown risks, uncertainties, and actual results or future events expressed or implied. It is inevitably based on many estimates and assumptions that are affected by other factors. By description of such future prospects. Such factors include, but are not limited to: General business, economic, competitive, political and social uncertainties. MediPharm Labs is unable to raise adequate funding. Delays or failures in regulatory approval. And other factors described in the MediPharm Labs filing. It is available on the SEDAR website (www.sedar.com). Actual results and future events may differ materially from those expected in such statements and there is no guarantee that such statements will be proven to be accurate. Therefore, readers should not place excessive reliance on forward-looking statements or information contained in this news release. Except as required by law, MediPharm Labs shall not be obligated to update any forward-looking statements, opinions, forecasts, or other factors.

All information contained in this press release regarding Avicanna was provided by Avicanna for inclusion here.


CBJ News Maker

MediPharm Labs Completes Export of Medical Cannabis to Barbados, Canadian Business Journal

Source link MediPharm Labs Completes Export of Medical Cannabis to Barbados, Canadian Business Journal

Related Articles

Back to top button